If a patient thinks they are on a treatment, they might actually end up healthier than a patient who has just been told there are no treatment options left for them...
Likewise, if a clinician is really hoping the new drug they are developing is successful, their judgement of exactly how quickly a tumour is growing might not be fully impartial.
However, there is no need for the control group and treatment group to be 50/50. The control group can also be shared with other studies - although that makes risk budget allocation complex, but not impossible.